Sep 27

Scientific

SS 03 - Technologically Driven strategies in HPVrelated OPSCC

03:00pm - 04:00pm ET

Head and Neck Cancer

MODERATOR(S)

Niema Razavian, MD - Moffitt Cancer Center

Sharon Spencer, MD - University of Alabama at Birmingham

Credits

AMA PRA Category 1 Credits:

1.25

Rate This Session

Presentations

03:00pm - 03:10pm ET

Pooled Analysis of Prospective Trials of FMISO PET-Guided 30Gy De-Escalation in HPV-Positive Oropharyngeal Cancer Demonstrating Reduced Toxicity with Durable Long-Term Control

Speaker: Nancy Lee, MD, FASTRO - Memorial Sloan Kettering Cancer Center, New York
03:10pm - 03:20pm ET

HYpofractionated, Dose-redistributed RAdiotherapy (HYDRA) with Protons or Photons vs. Standard of Care for Head and Neck Squamous Cell Carcinoma: A Randomized Trial

Speaker: Pascal Gunsch, MD - Erasmus MC Cancer Institute, Department of Radiotherapy, Rotterdam
03:20pm - 03:30pm ET

TRINITY-HPV: Transoral RobotIc surgery (TORS) Followed by deinteNsified Post-OperatIve ChemoradioTherapY (CRT) in HPV-Associated Oropharyngeal Carcinoma (OPC)

Speaker: Zachary Zumsteg, MD - Cedars-Sinai Medical Center, Los Angeles
03:30pm - 03:40pm ET

MR-ADAPTOR: Randomized Phase II Trial of Weekly MRI-Guided Volumetric Adaptation and Elective Neck Deintensification for Low-Risk HPV-Associated OPSCC

Speaker: Warren Floyd, MD, PhD, BS - MD Anderson Cancer Center, Houston
03:40pm - 03:50pm ET

Oncologic Outcomes of a Multicenter Prospective Study Evaluating ctHPVDNA-Adapted Adjuvant Radiotherapy in Patients with HPV-Associated Oropharyngeal Cancer

Speaker: James Bates, MD - Emory University, Atlanta
03:50pm - 04:00pm ET

Discussant

Speaker: C Jillian Tsai, MD, PhD, MS - Princess Margaret Cancer Centre, Toronto